Advertisement

World Journal of Surgery

, Volume 7, Issue 3, pp 390–399 | Cite as

An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British stomach cancer group

  • J. W. L. Fielding
  • S. L. Fagg
  • B. G. Jones
  • D. Ellis
  • M. S. Hockey
  • A. Minawa
  • V. S. Brookes
  • J. L. Craven
  • M. C. Mason
  • A. Timothy
  • J. A. H. Waterhouse
  • P. F. M. Wrigley
Original Scientific Reports

Abstract

A prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer was commenced in 1976. Four hundred and eleven patients have been randomized into 1 of 3 treatment groups. Group A received a placebo injection of intravenous normal saline (10 ml) at 3-week intervals. Group B received a 5-day induction course of 5-fluorouracil (5-FU), vincristine, cyclophosphamide, and methotrexate followed by 3-week intravenous injections of 5-FU and mitomycin C (MMC). Group C received 3-week intravenous injections of 5-FU and MMC. The treatment was to be given for 2 years. Patients were stratified for age, sex, preoperative duration of symptoms, and clinicopathological stage prior to randomization. At this interim analysis, preoperative duration of symptoms and clinicopathological stage were statistically significant prognostic factors (p=<0.05 and <0.001, respectively).

At the time of this analysis, there has been no significant improvement in survival in either of the treatment groups compared to the control group. While treatment could begin at any time during the first 3 postoperative months, survival at 1 year was significantly improved (p=0.013) by treatment C in those who started treatment within 1 month of surgery; however, this benefit of treatment was not maintained at 3 years. Of the 279 deaths, 16 (5.7%) have been drug-related, 11 resulting from renal toxicity associated with this therapeutic regimen.

This study has confirmed the poor prognosis of gastric cancer, and the early results demonstrate that there is no place for the use of cytotoxic agents in this disease outside prospective controlled studies.

frRésumé

Une étude prospective organisée et contrÔlée de la chimiothérapie complémentaire de la chirurgie du cancer de l'estomac opéré a commencé en 1976.

411 malades ont été répartis en trois groupes. Les opérés du groupe A ont reÇu un placébo, c'est-àdire une injection intraveineuse de 10 ml de sérum salé isotonique à 3 semaines d'intervalle. Ceux du groupe B ont reÇu d'abord durant 5 jours du 5-fluorouracil (5FU), de la vincristine, de la cyclophosphaline et du methotrexate puis toutes les trois semaines des injections de 5FU et de mitomycine (MMC). Enfin ceux du groupe C ont reÇu toutes les semaines des injections de 5FU et de MMC. Le traitement a duré deux ans.

Avant la randomisation, les patients ont été répartis selon l'âge, le sexe, la durée des symptÔmes, le stade anatomoclinique. L'analyse provisoire a permis de constater que la durée des symptÔmes avant l'intervention et que le stade anatomo-clinique atteint par le cancer étaient des facteurs de pronostic statistiquement significatifs (P=<0.05 et <001 rétrospectivement). Au terme de l'analyse, on peut cependant affirmer qu'il n'y a pas d'amélioration du taux de la survie des malades traités par rapport à ceux qui reÇurent un placebo. S'il est à remarquer que la survie à un an a été significativement améliorée (P=0,013) quand le traitement de type C a débuté au plus tard un mois avant l'intervention, le bénéfice de la chimiothérapie ne se maintient pas à trois ans. Enfin, sur les 279 morts dénombrés, 16 (5,7%) peuvent Être attribués à l'emploi des agents cytotoxiques, 11 de ces morts relevant de la toxicité pour le rein de ces drogues.

Cette étude confirme le pronostic sévère du cancer de l'estomac et les résultats démontrent qu'il n'y a réellement pas de place pour l'emploi d'agents cytotoxiques dans le traitement du cancer de l'estomac.

Keywords

Como Stomach Cancer Mese Este Regimen Clinicopathological Stage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abstracto

En 1976 se inició un estudio prospectivo, al azar y controlado de la quimioterapia coadyuvante en cáncer gástrico operable. Cuatrocientos once patientes fueron asignados al azar a 1 de 3 grupos de tratamiento. El grupo A recibió placebo en forma de una inyección intravenosa de solución salina normal (10 ml) a intervalos trisemanales. El grupo B recibió un curso de 5 días de inducción de 5-fluoruracilo (5-FU), vincristina, ciclofosfamida y metotrexato seguido de inyecciones de 5-FU en inyecciones trisemanales de 5-FU y mitomicina C (MMC). El grupo C recibió inyecciones trisemanales de 5-FU y MMC. El tratamiento ha sido proyectado para 2 años. Los pacientes fueron estratificados por edad, sexo, duración preoperatoria de los síntomas, y estado clínico patológico anterior a la asignación al azar. En el momento de este análisis preliminar, la duraćion preoperatoria de los síntomas y el estado clínicopatologico aparecen como factores de pronóstico de significaćion estadística (p=<0.05 y <0.001, respectivamente).

En la fecha de este análisis no se ha observado ninguna mejoría significativa en la supervivencia en ninguno de los grupos de tratamiento comparados con el grupo control. Aun cuando el tratamiento puede iniciarse en cualquier momento en el curso de los primeros 3 meses, la supervivencia a 1 año fue significativamente mejor (p=0.013) con el tratamiento C en aquellos pacientes que comenzaron tratamiento dentro del mes siguiente a la cirugía; sin embargo, este beneficio del tratamiento no fue mantenido a los 3 años. De las 279 muertes, 16 (5.7%) han estado relacionadas con las drogas, 11 como resultado de toxicidad renal asociada con este regimen terapéutico.

Este estudio ha confirmado el pobre pronóstico del cáncer gástrico, y los resultados preliminares demuestran que no existe lugar para el uso de agentes citotóxicos por fuera de estudios prospectivos controlados, en esta enfermedad.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    1979 Mortality statistics—cause. England and Wales. Office of Population Census and Surveys. Malignancies and neoplasms of the stomach, p. 10Google Scholar
  2. 2.
    Waterhouse, J.A.H.: Cancer Handbook of Epidemiology and Prognosis. Edinburgh, Churchill Livingstone, 1974Google Scholar
  3. 3.
    Swynnerton, R.F., Truelove, S.C.: Carcinoma of the stomach. Br. Med. J.1:287, 1952Google Scholar
  4. 4.
    Takagi, K.: Stages of gastric cancer and reconstruction after surgery. In Gastric Cancer: Advances in the Biosciences, vol. 32, J.W.L. Fielding, C.E. Newman, C.H.J. Ford, B.G. Jones, editors, Oxford, Pergamon Press, 1981, pp. 191–202Google Scholar
  5. 5.
    Fielding, J.W.L., Ellis, D.J., Jones, B.G., Paterson, J., Powell, D.J., Waterhouse, J.A., Brookes, V.S.: Natural history of “early” gastric cancer: Results of a 10-year regional survey. Br. Med. J.281:965, 1980Google Scholar
  6. 6.
    Gunderson, L.: Radiation therapy: Results and future possibilities. Clin. Gastroenterol.5:743, 1976Google Scholar
  7. 7.
    Kajitani, T., Miwa, K.: Treatment results of stomach carcinoma in Japan 1963–1966. WHO-CC Monograph 2, Tokyo, WHO, 1979Google Scholar
  8. 8.
    Gilbertson, V.A.: Results of treatment of stomach cancer. Cancer23:1305, 1969Google Scholar
  9. 9.
    Comis, R., Carter, S.: A review of chemotherapy in gastric cancer. Cancer34:1576, 1974Google Scholar
  10. 10.
    Rake, M.O., Mallinson, C.N., Cocking, B.J., Cwynarski, M.C., Fox, C., Jackson, A., Diffey, B.: Assessment of the value of cytotoxic therapy in treatment of carcinoma of the stomach. Gut17:832, 1976Google Scholar
  11. 11.
    Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J., Smith, P.G.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer35:1, 1977Google Scholar
  12. 12.
    Brookes, V.S., Waterhouse, J.A.H., Powell, J.: Carcinoma of the stomach: 10-year survey of results and of factors affecting prognosis. Br. Med. J.1:1577, 1965Google Scholar
  13. 13.
    Smith, F.P., Cambareri, R.J., Killen, J.Y., et al.: Gastrointestinal cancer. In Cancer Chemotherapy: The EORTC Cancer Chemotherapy Annual 2, H. Pindeo, editor, Amsterdam, Excerpta Medica, 1980, pp. 284–298Google Scholar
  14. 14.
    Kovach, J.S., Moertel, C.G., Schutt, A.J., Hahn, R.G., Reitemeier, R.J.: A controlled study of 1, 3, BIS-(2 chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric cancer and pancreatic cancer. Cancer33:563, 1974Google Scholar
  15. 15.
    Reitemeier, R.J., Moertel, C.G., Hahn, R.G.: Combination chemotherapy in gastrointestinal cancer. Cancer Res.30:1425, 1970Google Scholar
  16. 16.
    Hanham, I., Newton, K., Westbury, G.: 75 cases of solid tumours treated by a modified quadruple chemotherapy regime. Br. J. Cancer25:462, 1971Google Scholar
  17. 17.
    Kingston, R.D., Ellis, D.J., Powell, J., Brookes, V.S., Waterhouse, J.A., Hurst, M.D., Smith, J.A.: The West Midlands gastric carcinoma chemotherapy trial: Planning and results. Clin. Oncol.4:55, 1978Google Scholar
  18. 18.
    Imanaga, H., Nakazoto, H.: Results of surgery for gastric cancer and the effect of adjuvant mitomycin C on cancer recurrence. World J. Surg.1:213, 1977Google Scholar
  19. 19.
    Franz, J.L., Cruz, A.B.: The treatment of gastric cancer with combined surgical dissection and chemotherapy. J. Surg. Oncol.9:131, 1977Google Scholar
  20. 20.
    Lundh, G., Burn, J.I., Kolig, G., et al.: A cooperative international study of gastric cancer. Ann. R. Coll. Surg. Engl.54:219, 1974Google Scholar
  21. 21.
    Jones, B.G., Fielding, J.W.L., Newman, C.E., Howell, A., Brookes, V.S.: Intravascular haemolysis and renal impairment after blood transfusion in two patients on long term 5-Fluorouracil and Mitomycin C. Lancet1:1275, 1980Google Scholar
  22. 22.
    Rumpf, K.W., Reiger, J., Lankisch, P.G., von Heyden, H.W., Nagel, G.A., Scheler, F.: Mitomycin C induced haemolysis and renal failure. Lancet2:1037, 1980Google Scholar
  23. 23.
    Jones, B.G. (for the Stomach Cancer Group): Design and progress of a multi-centre trial of adjuvant chemotherapy in operable gastric cancer. In Progress and Perspectives in the Treatment of Gastrointestinal Tumours, A. Gerard, editor, Oxford, Pergamon Press, 1981, pp. 36–40Google Scholar
  24. 24.
    Nakajima, T., Kajitani, T.: Surgical treatment of gastric cancer with special reference to lymph node dissection. In Diagnosis and Treatment of Upper Gastrointestinal Tumours, M. Friedman, M. Ogawa, D. Kisner, editors, Amsterdam, Excerpta Medica, 1981, pp. 207–223Google Scholar
  25. 25.
    The Gastrointestinal Tumour Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer49:1116, 1982Google Scholar
  26. 26.
    Bitran, J.D., Desser, R.K., Kozloff, M.F., Billings, A.A., Shapiro, C.M.: Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-Fluorouracil, Adriamycin and Mitomycin C. Cancer Treat. Rep.63:2049, 1979Google Scholar
  27. 27.
    Levi, J.A., Dalley, D.N., Aroney, R.S.: Improved combination chemotherapy in advanced gastric cancer. Br. Med. J.2:1471, 1979Google Scholar
  28. 28.
    Robinson, E., Cohen, Y.: The combination of surgery, radiotherapy and chemotherapy in the treatment of gastric cancer. Recent Results Cancer Res.32:177, 1977Google Scholar
  29. 29.
    Moertel, C.G., Childs, D.S., Jr., Reitemeier, R.J., Colby, M.Y., Jr., Holbrook, M.A.: Combined 5-Fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet2:865, 1969Google Scholar
  30. 30.
    Catterall, M., Kingsley, D., Lawrence, G., Grainger, J., Spencer, J.: The effects of fast neutrons on inoperable carcinoma of the stomach. Gut16:150, 1975Google Scholar

Copyright information

© Société Internationale de Chirurgie 1983

Authors and Affiliations

  • J. W. L. Fielding
    • 1
    • 2
    • 3
    • 4
    • 5
  • S. L. Fagg
    • 1
    • 2
    • 3
    • 4
    • 5
  • B. G. Jones
    • 1
    • 2
    • 3
    • 4
    • 5
  • D. Ellis
    • 1
    • 2
    • 3
    • 4
    • 5
  • M. S. Hockey
    • 1
    • 2
    • 3
    • 4
    • 5
  • A. Minawa
    • 1
    • 2
    • 3
    • 4
    • 5
  • V. S. Brookes
    • 1
    • 2
    • 3
    • 4
    • 5
  • J. L. Craven
    • 1
    • 2
    • 3
    • 4
    • 5
  • M. C. Mason
    • 1
    • 2
    • 3
    • 4
    • 5
  • A. Timothy
    • 1
    • 2
    • 3
    • 4
    • 5
  • J. A. H. Waterhouse
    • 1
    • 2
    • 3
    • 4
    • 5
  • P. F. M. Wrigley
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Department of Surgery, Surgical Immunology Unit, and Regional Cancer RegistryQueen Elizabeth Hospital and Medical CenterBirminghamEngland
  2. 2.York District HospitalYorkEngland
  3. 3.Singleton HospitalWest Glam
  4. 4.St. Thomas's HospitalLondonEngland
  5. 5.Department of Medical OncologySt. Bartholomew's HospitalLondonEngland

Personalised recommendations